| CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer S Rizzo, F Petrella, V Buscarino, F De Maria, S Raimondi, M Barberis, ... European radiology 26, 32-42, 2016 | 279 | 2016 |
| Pulmonary sarcomatoid carcinomas: a practical overview G Pelosi, A Sonzogni, T De Pas, D Galetta, G Veronesi, L Spaggiari, ... International journal of surgical pathology 18 (2), 103-120, 2010 | 225 | 2010 |
| Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations T De Pas, F Toffalorio, M Manzotti, C Fumagalli, G Spitaleri, C Catania, ... Journal of Thoracic Oncology 6 (11), 1895-1901, 2011 | 145 | 2011 |
| Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung A Marchetti, L Felicioni, G Pelosi, M Del Grammastro, C Fumagalli, ... Human mutation 29 (5), 609-616, 2008 | 97 | 2008 |
| Temozolomide in advanced neuroendocrine neoplasms: pharmacological and clinical aspects A Koumarianou, G Kaltsas, MH Kulke, K Oberg, JR Strosberg, F Spada, ... Neuroendocrinology 101 (4), 274-288, 2015 | 91 | 2015 |
| Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1Cin pancreatic endocrine tumors G Malpeli, E Amato, M Dandrea, C Fumagalli, V Debattisti, L Boninsegna, ... BMC cancer 11, 1-12, 2011 | 89 | 2011 |
| Molecular testing for targeted therapy in advanced Non–Small cell lung cancer: suitability of endobronchial ultrasound transbronchial needle aspiration C Casadio, J Guarize, S Donghi, C Di Tonno, C Fumagalli, D Vacirca, ... American Journal of Clinical Pathology 144 (4), 629-634, 2015 | 79 | 2015 |
| SARS-CoV-2 detection in formalin-fixed paraffin-embedded tissue specimens from surgical resection of tongue squamous cell carcinoma E Guerini-Rocco, SV Taormina, D Vacirca, A Ranghiero, A Rappa, ... Journal of Clinical Pathology 73 (11), 754-757, 2020 | 47 | 2020 |
| Dual role of RASSF1 as a tumor suppressor and an oncogene in neuroendocrine tumors of the lung G Pelosi, C Fumagalli, M Trubia, A Sonzogni, N Rekhtman, ... Anticancer research 30 (10), 4269-4281, 2010 | 44 | 2010 |
| Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses C Fumagalli, A Ranghiero, S Gandini, F Corso, S Taormina, E De Camilli, ... Breast Cancer Research 22, 1-11, 2020 | 42 | 2020 |
| A systematic review and meta‐analysis of the prognostic role of age in oral tongue cancer M Tagliabue, P Belloni, R De Berardinis, S Gandini, F Chu, S Zorzi, ... Cancer Medicine 10 (8), 2566-2578, 2021 | 39 | 2021 |
| Methylation of O 6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients C Fumagalli, G Pruneri, P Possanzini, M Manzotti, M Barile, I Feroce, ... Breast cancer research and treatment 134, 131-137, 2012 | 39 | 2012 |
| Understanding EGFR heterogeneity in lung cancer A Passaro, U Malapelle, M Del Re, I Attili, A Russo, E Guerini-Rocco, ... ESMO open 5 (5), e000919, 2020 | 38 | 2020 |
| Recurrent NAB2–STAT6 gene fusions and oestrogen receptor‐α expression in pulmonary adenofibromas N Fusco, E Guerini‐Rocco, C Augello, A Terrasi, G Ercoli, C Fumagalli, ... Histopathology 70 (6), 906-917, 2017 | 38 | 2017 |
| Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis Z Li, Y Wu, ME Yates, N Tasdemir, A Bahreini, J Chen, KM Levine, ... Cancer research 82 (7), 1321-1339, 2022 | 35 | 2022 |
| Breast cancer heterogeneity C Fumagalli, M Barberis Diagnostics 11 (9), 1555, 2021 | 35 | 2021 |
| Pathologic and molecular features of screening low-dose computed tomography (LDCT)-detected lung cancer: a baseline and 2-year repeat study G Pelosi, A Sonzogni, G Veronesi, E De Camilli, P Maisonneuve, ... Lung Cancer 62 (2), 202-214, 2008 | 32 | 2008 |
| Genomic characterization of concurrent alterations in Non-Small Cell Lung Cancer (NSCLC) harboring actionable mutations A Passaro, I Attili, A Rappa, D Vacirca, A Ranghiero, C Fumagalli, ... Cancers 13 (9), 2172, 2021 | 31 | 2021 |
| Immunotherapy in breast cancer patients: a focus on the use of the currently available biomarkers in oncology C Criscitiello, E Guerini-Rocco, G Viale, C Fumagalli, E Sajjadi, K Venetis, ... Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2022 | 30 | 2022 |
| Tumor BRCA test for patients with epithelial ovarian cancer: the role of molecular pathology in the era of PARP inhibitor therapy C Fumagalli, F Tomao, I Betella, A Rappa, M Calvello, B Bonanni, ... Cancers 11 (11), 1641, 2019 | 29 | 2019 |
